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Background: There is exist an opinion about a higher resistance of CF patients to
M. tuberculosis.
However, a chronic pulmonary disease with damaged clearance, poor nutritional
status, diabetes mellitus, frequent glucocorticosteroids usage are an obvious predis-
posing factors of TB infection in CF patients.
Objective: To demonstrate clinical signiﬁcance and difﬁculties of TB infection
diagnosis in CF patients.
Methods: Information about TB cases in CF patients in Russia and France.
The results of the clinico-radiological, bacteriological investigations, data of skin
tuberculin tests, M. tuberculosis sensitivity to antituberculous drugs.
Results: We have got information about 10 cases (7 in Russia and 3 in France)
of pulmonary tuberculosis and cystic ﬁbrosis combination. Due to the similarity of
clinical and radiological picture in none of the patients the diagnosis was based on
clinical symptoms. Bacteriologic diagnosis was the predominant creation. At the
early stages tuberculosis was diagnosed only by scheduled microbiologic tests for
M. tuberculosis in sputum on Loewenstein cultures. The peculiarity of tuberculosis
in Russia was multiresistant M. tuberculosis strains identiﬁcation.
Conclusion: Tuberculosis in CF patients in its active detection is not rare and
presents a potentially serious complication.
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Background: The impact of airways colonization by Exophiala dermatitidis (ED)
on the clinical course of CF patients is unknown.
Methods: We conducted a retrospective case–control study among non lung-
transplanted patients followed at our centre (mean number of cultures/2 y: 13). Index
cases were deﬁned as patients with one or more sputum cultures + for ED over a
2 years period (Group A). Each ED+ patient was carefully matched with a single
ED− control, taking into account age, gender, genotype, BCC and Ps. aeruginosa
status (Group B). The two groups were then compared at the end of the period in
terms of FEV1, rate of FEV1 decline over the past 3 years, BMI (Z-score), IgG
levels, Aspergillus fumigatus (Asp f) colonization, predominant bacterial pathogen
abd treatment. Speciﬁc precipitating antibodies against ED and Asp f were also
investigated.
Results: ED was isolated in 9 patients (5.8%). No signiﬁcant difference of clinical
status or previous treatment was found between Groups A and B. Restricting the
analysis to the 6 patients chronically colonized by ED and their controls did not
modify the conclusions.
In a single patient from group A, without ABPA, only fungi were isolated over the
2 years (ED: 14/20±Asp f: 9/20). A continuous use of voriconazole resulted in a
dramatic and sustained decrease of her bronchorrhea.
Conclusion: A deleterious effect on the clinical course could not be demonstrated
by this case-control study.
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Background: Allergic bronchopulmonary Aspergillosis (ABPA) is an complex
hypersensitivity reaction that occurs when bronchi become colonized with As-
pergillus. ABPA occurs in approximately 10% of the CF patients. The mainstay
of treatment is oral corticosteroid therapy, but this may need to be continued for
several months and is associated with signiﬁcant adverse effects. Itraconazole in
addition to glucocorticoids is of beneﬁt to reduce steroid dosage.
There is increasing evidence for the efﬁcacy of the antifungal voriconazole. We
describe our experience of using voriconazole in children with CF.
Methods: We reviewed the ﬁles of CF patients treated with voriconazole in our
centre over the last 26 months.
Results: Six patients (age 7 y, 11m to 24 y, 10m − median age 16 y, 9m) received
voriconazole as monotherapy for treatment of ABPA and/or invasive aspergillosis.
In 2 patients voriconazole was started because of invasive aspergillosis secondary to
steroid treatment for ABPA, in 4 patients because of severe side effects to previous
ABPA treatment with corticoisteroids. Patients were treated for six months. All
patients improved in pulmonary function and ABPA markers (eosinophilia, tot IgE,
speciﬁc IgE). Up-to-date, after a follow-up of 2−20 months (median follow-up-
period 6 months) after the end of treatment in 5 patients, 1 patient relapsed 4 months
after treatment, 4 patients showed sustained improvement in pulmonary function and
ABPA markers and 1 patient is still on voriconazole treatment.
Conclusion: Our results conﬁrm previous reports. Voriconazole monotherapy ap-
pears to be an alternative treatment strategy when oral corticosteroids are not be
suitable.
206 Methicillin resistant Staphylococcus aureus (MRSA) colonisation
in cystic ﬁbrosis patients
G. Garcia-Hernandez1, M.T. Martinez1, F. Chaves2, A. Martinez-Gimeno3,
C. Luna3, C. Garﬁa1, J. Manzanares1. 1Hospital Universitario 12 de Octubre,
Unidad de Fibrosis Quistica, Madrid, Spain; 2Hospital Universitario 12 de
Octubre, Microbiologı´a, Madrid, Spain; 3Hospital Universitario 12 de Octubre,
Neumologı´a Infantil, Madrid, Spain
Isolation of methicillin-resistant Stahpylococcus aureus has increased its incidence
in cystic ﬁbrosis units, although its prevalence varies amongst centers. The purpose
of this study was to estimate prevalence of this pathogen in our unit and assess risk
factors that could affect its emergence.
We reviewed microbiological cultures from the 105 patients in our Unit. Two age-
matched controls (patients who had never been MRSA-positive) were selected for
each case (colonised with MRSA). Shwachman clinical and Bradsﬁeld chest X-ray
scores, as well as best lung function from past year were collected.
Twelve (6 males) patients were colonised with MRSA, prevalence of 11.4%.
Mean age was 28.4 years (SD 5.8). Nine cases had previous data of MRSA
acquisition, 16 in the control group. Mean age at acquisition was 26.4 years
(SD 5.5). No differences between MRSA group and controls was observed regarding
the following variables: clinical scores, lung function tests, colonisation by other
pathogens, hospitalisation rates or previous antibiotic therapy, whether it was oral,
intravenous or inhaled. Signiﬁcant difference was identiﬁed in X-ray scores, which
were worse in the MRSA group: 15.7±3.71 vs 19.91±5.26 (CI 95% 0.3−8) p< 0.03.
Prevalence of MRSA in our group is moderate. There were no paediatric cases.
Poorer X-ray scores in the MRSA group could reﬂect more impact of pulmonary
symptoms.
